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Abstract
Etanercept, a TNF receptor 2-Fc fusion protein, is currently being used for the treatment of rheumatoid arthritis (RA).
However, 25% to 38% of patients show no response which is suspected to be partially due to insufficient affinity of this
protein to TNFa. By using computational protein design, we found that residue W89 and E92 of TNFR2 were critical for
ligand binding. Among several mutants tested, W89Y/E92N displayed 1.49-fold higher neutralizing activity to TNFa,a s
compared to that of Etanercept. Surface plasmon resonance (SPR) based binding assay revealed that the equilibrium
dissociation constant of W89Y/E92N to TNFa was 3.65-fold higher than that of Etanercept. In a rat model of collagen-
induced arthritis (CIA), W89Y/E92N showed a significantly better ability than Etanercept in reducing paw swelling and
improvement of arthritic joint histopathologically. These data demonstrate that W89Y/E92N is potentially a better candidate
with improved efficacy in treating RA and other autoimmune diseases.
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Introduction
Overproduction of TNFa is an underlying mechanism of
autoimmune diseases, including RA, ankylosing spondylitis and
psoriatic arthritis [1–2]. Blocking excess TNFa by its antagonists
including TNF receptor 2-IgG1 fusion protein (Etanercept) and
anti-TNFa monoclonal antibodies (Infliximab and Adalimumab)
has been validated as an effective treatment for RA [1,3–4],
although not all patients respond well to the treatment (25% to
38% of Etanercept patients; 21% to 42% of Infliximab patients).
Etanercept has been shown to be efficacious in a proportion of
patients who did not respond to Infliximab, and vice versa [5].
The failure of Etanercept in some RA patients and in some
autoimmune diseases, such as Crohn’s disease, was likely due to its
low affinity to TNFa [6–8]. A higher affinity TNFR2-Fc variant is
believed to possess better efficacy than Etanercept.
We developed some higher affinity TNFR2-Fc variants by
computational protein design method. Since the structures of
TNFR2-TNFa complex and TNFR2 were absent, we chose 1a8m
and 1tnr, the crystal structure of a TNFa variant and a complex of
TNFR1 and TNFb in protein data bank, as templates to model
the interactions of TNFR2-TNFa. TNFa and TNFb share high
sequence identity and similar binding characters to two common
receptors, TNFR1 and TNFR2, containing 4 highly conserved
cysteine rich domains within the extracellular region [9–10]. We
therefore constructed the TNFR2-TNFb model by molecular
modeling software package InsightII (Accelrys Inc.). According to
the model, we found that the amino acid residues 89 and 92 of
TNFR2 are critical for binding with TNFa and the corresponding
mutants were expressed in a mammalian cell system (CHO-K1
cells). A mutant with combined mutation at these two sites,
W89Y/E92N, displayed improved activity against TNFa in both
in vitro and in vivo assays. Here we report the design and
characterization of this high affinity TNFR2-Fc variant, and focus
on evaluating its therapeutic effect of neutralizing activity of TNFa
on RA.
Results
Residues W89 and E92 of TNFR2 are critical for ligand
binding. We modeled the TNFR2-TNFa complex with the
template 1a8m and 1tnr by the computer program Homology, a
module within InsightII, the backbone of the TNFR1 in 1tnr was
substituted by the corresponding residues of TNFR2, the
construction of disulfide bonds was referenced to Banner’s
models [10–11], and the overall structure of TNFb in 1tnr was
replaced by TNFa of 1a8m. The TNFR2-TNFa interactions were
optimized by Amber force-field in the Discover module of
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TNFa mainly through the second cysteine rich domain, and
residue W89 and E92 of TNFR2 is crucial for binding with loop
29–34 and 85–89 of TNFa. The sketch map of TNFR2-TNFa
interactions is shown in Fig. 1 A, and the specific interactions of
residue W89 and E92 of TNFR2 with TNFa are depicted in Fig. 1
B and C. Residue W89 and E92 appear to interact with Y87, and
N34 of TNFa, respectively. The binding energy of W89 and 92 to
the counterparts of TNFa also prompted their importance in
ligand binding (data not shown). We therefore chose residues 89
and 92 for further mutagenesis studies.
TNFR2-Fc variants with residue 89 and 92 mutation
displayed improved activity in neutralizing the cytotoxic
effect of TNFa. Site-directed mutagenesis at amino acids 89
and 92 of TNFR2 was performed to determine the contribution of
these residues to the ligand binding properties, and the effect of
these variants on TNFa mediated cytotoxicity was characterized
by the neutralizing activity assay. As shown in Table 1, mutants
E92A, E92H and E92N, exhibited about 30% elevation of
neutralizing activity on TNFa; while the neutralizing activity of
mutant E92S decreased to only about 3% that of Etanercept;
residue 89 substituted by H, F, I and M also impaired the
neutralizing activity on TNFa greatly. Theses results confirmed
the importance of residue 89 and 92 to binding with TNFa.B y
studying mutagenesis at 92 and 89 simultaneously, we generated
W89Y/E92N, E92S/W89Y and E92N/W89F mutants and found
that the combined mutations had enhanced neutralizing activity
against TNFa. W89Y/E92N, the most potent variant in the
neutralizing assay, was selected for further evaluation.
W89Y/E92N mutant exhibits higher binding affinity for
TNFa. The binding kinetics data of the W89Y/E92N and
TNFR2 was obtained using the SPR technique (Table 2).
Compared with Etanercept, the equilibrium dissociation
constant (KD) of W89Y/E92N for TNFa showed a 3.65-fold
decrease, which meant the affinity of W89Y/E92N to TNFa was
enhanced. The binding kinetics indicates that the ligand binding
mode of W89Y/E92N might differ from that of Etanercept.
Specifically, the dissociation kinetic constant (kd) of W89Y/E92N
for TNFa (1.29610
26 s
21) was markedly lower than that of
Etanercept (4.1610
26 s
21); while the association kinetic constant
(ka) of W89Y/E92N (9.72610
3 M
21s
21) for TNFa was only a
Figure 1. The overall structure of TNFR2-TNFa. The model was
homologically modeled with the templates 1tnr and 1a8m, the TNFb-
TNFR1 complex and a TNFa variant crystal structure. (A) The model
structure of TNFR2-TNFa complex. TNFR2 are shown using purple and
blue cartoons, while TNFa is in red. (B) The specific interactions of
residue W89 (TRP) of TNFR2 with TNFa. (C) The specific interactions of
residue E92 (Glu) of TNFR2 with TNFa.
doi:10.1371/journal.pcbi.1000669.g001
Author Summary
Rheumatoid arthritis (RA) is a frequently occurring, chronic,
debilitating disease. TNFa plays a pivotal role in regulating
its inflammatory response. TNFa inhibition with TNF
receptor 2-Fc fusion protein (TNFR2-Fc) was effective in
the treatment of RA. However, quite a few patients may
not achieve good clinical outcomes after TNFR2-Fc
therapy, and the high dosage of TNFR2-Fc in clinical
treatment usually causes some side effects, such as
injection site reactions. Enhancing the affinity of TNFR2-
Fc to TNFa would be of benefit to its therapeutic effect on
RA, and may reduce the clinical dosage. We modeled the
interactions of TNFa and TNFR2, and figured out the sites
that may be critical for ligand-receptor binding. A high
affinity TNFR2-Fc variant (E92N/W89Y) was obtained by
rational mutagenesis at residue 89 and 92. It shows
significant improvements compared with wild type TNFR2-
Fc in suppressing rat arthritis induced by collagen. This
variant is more potent in neutralizing TNFa, and thereafter
may offer a higher degree of RA symptom relief, and be in
a much lower dosage.
A TNFR2-Fc Variant for Rheumatoid Arthritis
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3 M
21s
21).
Therefore, we identify W89Y/E92N a higher affinity TNFR2-Fc
variant, and take notice of its lowered dissociation rate to TNFa
compared to Etanercept, which may improve its pathologic effect
in vivo.
W89Y/E92N possesses enhanced efficacy for the
treatment of CIA in rats. The in vivo effect of W89Y/E92N
and Etanercept was evaluated by employing a rat model of CIA,
and the paw swelling of rats was monitored throughout the period
of arthritis by drainage method [12]. W89Y/E92N and
Etanercept treatment reduced the paw swelling induced by
collagen compared to the normal saline treatment (untreated
group). Treatment with W89Y/E92N resulted in a dose-
dependent reduction in paw swelling over the treatment course
(Fig. 2), with doses of 3 and 9 mg/kg giving statistically significant
reductions in paw swelling relative to rats given the same dose of
Etanercept (P,0 05 and 0.01, respectively). After two week
therapy, Etanercept treatment at 1, 3 and 9 mg/kg lowered paw
swelling than the untreated group by 11.6, 15.2 and 16.2%,
respectively, while the same dose of W89Y/E92N treatment
reduced paw swelling by 20.9, 35.3 and 40.0% (Table 3). The
reduction of paw swelling rate following 3mg/kg and 9mg/kg of
W89Y/E92N treatment was 2.32 (35.3% vs 15.2%) and 2.47
(40.0% vs 16.2%) fold higher than that of the same dose of
Etanercept treatment.
The histopathologic changes of paw joints following W89Y/
E92N and Etanercept treatment in rats suffering from CIA was
shown in Fig 3. Characteristic of arthritic joints in rat CIA is
synovial hyperplasia, pannus formation, exudation of cells into the
joint space, and erosion of bone and cartilage [13]. A massive
influx of inflammatory cells, synovial hyperplasia, and accumula-
tion of abundant monomorphonuclear and polymorphonuclear
Table 1. The neutralizing activity of Etanercept and its
variants on TNFa-induced cytotoxicity in mouse L929 cells.
TNFR2-Fc proteins Neutralizing activity against TNFa (Unit/mg)
a
Etanercept 1.62610
6
W89H 4.14610
5
W89F 1.23610
6
W89I ,2.00610
4
W89Y 1.32610
6
W89M 4.00610
5
E92A 2.10610
6
E92S 4.86610
4
E92H 2.09610
6
E92N 2.12610
6
W89Y/E92N 2.42610
6
W89Y/E92S 2.16610
6
W89F/E92N 2.07610
6
a1 unit is the dose of Etanercept that neutralised the cytotoxic activity of 1 IU
TNFa on mouse L929 cells. Values are means of a triplicate experiment.
doi:10.1371/journal.pcbi.1000669.t001
Table 2. The binding kinetics profiles of the Etanercept and
W89Y/E92N to TNFa obtained by SPR.
Interaction ka
a (M
21s
21)k d
b (s
21)K D
c (nM)
TNF-Etanercept 8.45610
3 4.10610
26 0.485
TNF-W89Y/E92N 9.72610
3 1.29610
26 0.133
aAssociation kinetic constant.
bDissociation kinetic constant.
cEquilibrium dissociation constant. The SPR data were analyzed by
BIAevaluation software version 3.0.
doi:10.1371/journal.pcbi.1000669.t002
Figure 2. Paw-swelling. (A) Comparison of 1mg/kg Etanercept
treated vs. the same dose of W89Y/E92N. (B) Comparison of 3mg/kg
Etanercept treated vs. the same dose of W89Y/E92N. (C) Comparison of
9mg/kg Etanercept treated vs. the same dose of W89Y/E92N. Arrows
indicate the time of treatment. *, **, a significant reduction of paw
swelling of W89Y/E92N treatment compared to the groups given
Etanercept (P,0.05; P,0.01 student t test). There were 10 rats per
group. Black triangle, untreated group; Black diamond, 1mg/kg
Etanercept treated group; White diamond, 1mg/kg W89Y/E92N treated
group; Black square, 3 mg/kg Etanercept treated group; White square,
3mg/kg W89Y/E92N treated group; Black circle, 9 mg/kg Etanercept
treated group; White circle, 9mg/kg W89Y/E92N treated group.
doi:10.1371/journal.pcbi.1000669.g002
A TNFR2-Fc Variant for Rheumatoid Arthritis
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(Fig. 3 B) compared with non-immune group (Fig. 3 A). A reduced
degree of arthritis severity was observed in the rats that received
W89Y/E92N and Etanercept. By comparison, W89Y/E92N
treated group showed better joint histopathology amelioration
than the group treated with the same dosage of Etanercept.
Arthritic rats treated with 9mg/kg of W89Y/E92N showed the
minimal level of inflammation and joint destruction; specifically,
the synovial membrane in the joints looked like normal synovium,
with few signs of synovial hyperplasia or other characteristics of
inflammation (Fig 3 G). The pathologic improvement by W89Y/
E92N treatment indicates that this high affinity variant is a
potentially alternative of Etanercept in RA therapy.
Discussion
Computational protein design method has been demonstrated
to represent a valuable tool for the improvement and modification
of protein-protein interactions [14–15]. Etanercept is a dimeric
molecule that is 50- to 1000-fold more potent than a monomeric
form on the inhibition of TNFa activity in vitro, and thereafter
reaches the required bioactivity for proper therapeutic activity
[16–18]. Etanercept and its variants need to be prepared by the
eukaryocyte expression system and can not be screened by some
regularly high throughput methods. Modeling-guided specific
mutagenesis of interacting residues enables the protein evolution in
a limited region, and thereby accelerates the development of
candidates with potent activity.
The extracellular part of TNFR2 shared about 30% sequence
identity with TNFR1 and the alignment contains a long insertion
and some deletions between the CRD3 to CRD4 (data not shown),
it was difficult to model the whole structure of TNFR2 with
TNFR1 accurately. However, The CRD2 and CDR3 of TNFR2
showed a considerable degree of sequence identity with TNFR1
(,50%), consequently it was decided to model TNFR2 with the
backbone of TNFR1 in 1tnr, and focus on the specific interactions
of CDR2 and CDR3 of TNFR2 with its ligands. The TNFR2-
TNFa model showed that residue 89 and 92 of TNFR2 may affect
its binding to TNFa. The following site-directed mutagenesis
found that residue substitution at these points could obtain
potential candidates. We selected the variant W89Y/E92N for
further evaluation, which displayed improved anti-TNFa activity
in vitro. Consistent with results from neutralizing activity assays,
we found that W89Y/E92N variant had higher affinity to TNFa
than Etanercept, and had better pathologic improvement on
experimental RA in vivo.
Etanercept is known to have fast rates of association and
dissociation with TNFa. It releases TNFa within approximately
10 minutes, and again binds TNFa immediately [19]. When
receptor fusion concentration is relatively high, those released
TNFa will quickly reassociate with the receptor fusion and leave
rarely free in the system. However, under situations where TNFa
is released from the receptor fusion molecule and there are high
numbers of cell associated TNFa receptors present and a lower
level of receptor fusion (due to poor penetration), TNFa might
bind to the cell-associated TNFR1 or TNFR2 instead of back onto
the receptor fusion [20]. Thus it may be expected that W89Y/
E92N would have better neutralizing activity on TNFa in vivo for
its lowered dissociation rate compared with Etanercept
(1.29610
26 s
21 versus 4.10610
26 s
21).
W89Y/E92N exhibited significant improvement in suppressing
rat arthritis induced by collagen, presented lower paw swelling
after two weeks treatment than the same dosage of Etanercept and
better joint histopathology amelioration. The in vivo improvement
of W89Y/E92N may considerably ascribe to its high affinity, as
the pharmacokinetics profile of W89Y/E92N was comparable to
that of Etanercept (data not shown). The fact that only some RA
patients (about 40% Etanercept patients receiving 25 mg Etaner-
cept twice weekly for 24 weeks and 38.9% of patients receiving
MTX-6 mg/kg-Infliximab for 54 weeks) [20–21] showed a 50%
improvement in the American College of Rheumatology Index
makes a continued search for better therapeutants essential. There
was growing evidence that the efficacy of anti-TNFa therapies in
Crohn’s disease may critically depend on the affinity of TNFa
antagonists to TNFa [6–8]. Etanercept bound to TNFa with a 4-
fold lower affinity with respect to Infliximab, which was believed to
lead to the outcome that Crohn’s disease patients responded to
Infliximab but Etanercept [22]. The affinity of W89Y/E92N to
TNFa was close to that of Infliximab, and thereby could have
improved efficacy.
Materials and Methods
Modeling of TNFR2-TNFa complex. The crystal structure
of TNFb in complex with the TNFR1 is known as 1tnr in protein
data bank (PDB) [10], and the crystal structure of a TNFa variant
trimer as 1a8m in PDB. Data for 1tnr and 1a8m were used as
template to model the three-dimensional structure of complex of
Table 3. The alleviation effect of W89Y/E92N and Etanercept treatment on paw swelling in the rat model of CIA.
Treatment
The paw swelling on day
0 post-immunization (ml)
The paw swelling on day
31 post-immunization (ml) Increase (%)
Normal Saline 0.7160.04 1.2760.07 80.4613.2
1 mg/kg Etanercept 0.6960.05 1.1660.08 68.8613.1
3 mg/kg Etanercept 0.6860.05 1.1260.11 65.2615.4
9 mg/kg Etanercept 0.7160.03 1.1660.09 64.2616.3
1mg/kg W89Y/E92N 0.7360.03 1.1760.11 59.5614.5
3 mg/kg W89Y/E92N 0.7460.06 1.0660.07 45.1613.2
*
9 mg/kg W89Y/E92N 0.7160.03 1.0060.10 40.4614.9
**
Rats were immunized with CII, and at day 18 after the first immunization, rats that showed RA symptom were subcutaneously treated with normal saline (untreated
control group), 1, 3 and 9 mg/kg of Etanercept and W89Y/E92N, respectively, once per week for two consecutive weeks. Values are means6SD of ten rats for each
group. Differences between groups were examined for statistical significance by using student t test. *, P,0.05, **, P,0.01 compared with the same dosage of
Etanercept treatment.
doi:10.1371/journal.pcbi.1000669.t003
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InsightII (Accelrys software Inc.). The backbone of the TNFR1
in 1tnr was substituted by the corresponding residues of TNFR2,
the construction of disulfide bonds was referenced to Banner’s
models [10–11], and the overall structure of TNFb in 1tnr was
replaced by TNFa of 1a8m. The TNFR2-TNFa was refined with
Discover in Amber Force field. To that end, TNFR2-TNFa model
was optimized by applying 500 cycles of the steepest descent
method followed by 500 cycles of the conjugate gradient method,
respectively.
Generation of TNFR2-Fc mutants by site-directed
mutagenesis. Amino acid substitutions of TNFR2-Fc were
generated by PCR-based site-directed mutagenesis [23]. Two
pairs of primers were desired for overlapping PCR: the
Figure 3. Representative joint histopathology of the groups with CIA administered with W89Y/E92N and Etanercept. Tissue sections
from each group were stained with hematoxylin and eosin (HE). (A) None-immune group. (B) Untreated group treated with normal saline. (C) W89Y/
E92N 1mg/kg treated group. (D) Etanercept 1mg/kg treated group. (E) W89Y/E92N 3mg/kg treated group. (F) Etanercept 3mg/kg treated group. (G)
W89Y/E92N 9mg/kg treated group. (H) Etanercept 9mg/kg treated group. Scale shown on the right-hand side of (H) is equivalent to 0.1 mm.
doi:10.1371/journal.pcbi.1000669.g003
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GG) comprising Hind III restriction site prior to the ATG start
codon and a 24- to 36-mer reverse primer within TNFR2-Fc
coding region containing the desired mutation, another pair was
the forward primer complementary to the above reverse primer
and the reverse primer (59-gaattcctatttacccggagacaggg) comprising
EcoRI restriction site at the end of Fc coding sequence. The PCR
products of TNFR2-Fc mutants were digested with the Hind III
and EcoRI, and inserted into the pcDNA3 (Invitrogen).
Expression and purification of mutants. Plasmids were
amplified in the E. coli strain Top10F’ and extracted by a
commercial purification kit (Qiagen) following the manufacturer’s
instructions. CHO-K1 cells were transfected with a linear vector
encoding a TNFR2-Fc variant using lipofectamine 2000 based
protocol (Invitrogen). Stable transfectants were selected by
culturing in a medium containing Geneticin (G418, Sigma) and
selected clones were used for TNFR2-Fc protein production. The
proteins were purified by Protein A affinity chromatography. The
purity of recombinant proteins was analyzed by SDS-PAGE, and
the protein concentrations were determined by Bradford method
[24].
The neutralizing assay on TNFa-induced cytotoxicity in
mouse L929 cells. Mouse L929 cells were seeded into 96-well
microtiter plates at a density of 1.5610
4 cells/well in 100 mL
DMEM supplemented with 10% FBS. The cells were preserved at
37uC for 18h. 0.1ml 20units/ml TNFa (Sigma) in present of 2 mg/
ml actinomycin D (Sigma) was added per well, and then the cells
was incubated with gradient concentrations of Etanercept
(Amgen), TNFR2-Fc mutants or medium control for 24h at
37uC. Cell viability was measured by using a crystal violet staining
method [25]. All assays were performed in triplicate.
Surface plasmon resonance assay. The binding kinetics of
the Etanercept and W89Y/E92N for TNFa were analyzed by the
surface plasmon resonance technique (BIAcoreH 3000, G.E. Inc.).
Etanercept and W89Y/E92N were immobilized onto a CM5
sensor chip (G.E. Inc.), which resulted in an increase of 5000–5500
resonance units (RU). During the association phase, TNFa diluted
in running buffer (HBS-EP, 10 mM HEPES, 150 mM NaCl,
3 mM EDTA, 0.005% (v/v) surfactant P20, pH 7.4, Sigma) at
20.0, 10.0, 5.0, 2.5, 1.25, 0.625, 0.3125 nM, was allowed to pass
over the chips immobilized with Etanercept and W89Y/E92N,
respectively, at a flow rate of 40 ml/min for 1 min. During the
dissociation phase, HBS-EP buffer was applied to the sensor chip
at a flow rate of 40 ml/min for 2 min. The data were analyzed
globally with the BIAEVALUATION 3.0 software (BIAcoreH)
using a 1:1 Langmuir binding model [26].
The rat model of CIA. To assay for anti-TNFa
inflammation activity in vivo, a CIA assay was performed as
described [27–28]. In this model, female Wistar rats of
approximately 8 weeks old, weighing 150–180g, were obtained
from Shanghai Laboratory Animal Commission. (Shanghai,
China).The animals were acclimated to the holding room for at
least 7 days under the standard condition with free access to food
and water before initiation of the studies. For the induction of
CIA, the type II collagen (CII) (Sigma) was dissolved in 0.1M
acetic acid (Sigma) overnight, CII and incomplete Freund’s
adjuvant were homogenized at a 1:1 ratio to a final
concentration of 1 mg/ml. The mixture was stirred at 4uC for
overnight until the CII was completely emulsified. Each rat was
injected with 0.1ml emulsion per site intradermally at 4 sites on the
back and one site on the tail tip with a total of 0.5 ml (day 0). This
immunization protocol was repeated one more time seven days
post the first immunization (day 7). Induction and severity of
arthritis was determined by change in ankle weight, measured
using calipers. At day 18 after the first CII immunization, 70 rats
that showed RA symptom were chosen and randomly distributed
to 7 groups, 10 rats per group. Treated the inflammatory
comparison group (untreated control group) with normal saline,
the other groups with 1, 3, 9 mg/kg W89Y/E92N and 1, 3, 9mg/
kg Etanercept (Amgen), respectively. Besides randomly chose ten
rats that had not been immunized by CII as the blank control
group, and treated this group only with normal saline. The
administration of Etanercept and W89Y/E92N is once
subcutaneous per week for two consecutive weeks. The right
hind paw swelling was monitored by drainage with YLS-7A
calipers (Beijing Anjideer Inc., China) [12,29]. At last, these rats
were executed, and their right hind paw joints were prepared for
pathology analysis.
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